Extended Data Fig. 8: ctDNA dynamics throughout treatment in melanoma patients.
A Changes in circulating tumor DNA (increase or decrease) relative to the earliest sampled timepoint. Solid lines represent patients with recurrence or progressive disease, and dashed lines represent patients with either partial response or who are recurrence-free following treatment. Closed and open circles represent samples with and without detected ctDNA, respectively. B Difference in ctDNA relative to the pre-treatment timepoint stratified by clinical outcome. One sample did not have a pre-treatment timepoint available (MEL-15; progressive disease) and so a day 9 post-treatment time point was used as baseline. For boxplots in (B), the lower and upper ends of boxes represent the 25th and 75th percentiles of the data, respectively, and the horizontal lines represent the median. The whiskers represent at most 1.5 times the IQR. P-values were calculated using a two-sided Wilcoxon test.
